141 related articles for article (PubMed ID: 23815775)
21. HIV-1 gp120-CXCR4 recognition probed with synthetic nanomolar affinity D-peptides containing fragments of gp120 V3 loop.
Zhu R; Meng Q; Zhang H; Zhang G; Huang LSM; Xu Y; Schooley RT; An J; Huang Z
Eur J Med Chem; 2022 Dec; 244():114797. PubMed ID: 36270088
[TBL] [Abstract][Full Text] [Related]
22. Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120.
Cormier EG; Persuh M; Thompson DA; Lin SW; Sakmar TP; Olson WC; Dragic T
Proc Natl Acad Sci U S A; 2000 May; 97(11):5762-7. PubMed ID: 10823934
[TBL] [Abstract][Full Text] [Related]
23. Human complement proteins C3b, C4b, factor H and properdin react with specific sites in gp120 and gp41, the envelope proteins of HIV-1.
Stoiber H; Schneider R; Janatova J; Dierich MP
Immunobiology; 1995 Jun; 193(1):98-113. PubMed ID: 7590866
[TBL] [Abstract][Full Text] [Related]
24. Binding to CD4 of synthetic peptides patterned on the principal neutralizing domain of the HIV-1 envelope protein.
Autiero M; Abrescia P; Dettin M; Di Bello C; Guardiola J
Virology; 1991 Dec; 185(2):820-8. PubMed ID: 1720590
[TBL] [Abstract][Full Text] [Related]
25. Effect of amino acid substitution of the V3 and bridging sheet residues in human immunodeficiency virus type 1 subtype C gp120 on CCR5 utilization.
Suphaphiphat P; Thitithanyanont A; Paca-Uccaralertkun S; Essex M; Lee TH
J Virol; 2003 Mar; 77(6):3832-7. PubMed ID: 12610158
[TBL] [Abstract][Full Text] [Related]
26. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.
Nakamura GR; Byrn R; Wilkes DM; Fox JA; Hobbs MR; Hastings R; Wessling HC; Norcross MA; Fendly BM; Berman PW
J Virol; 1993 Oct; 67(10):6179-91. PubMed ID: 7690420
[TBL] [Abstract][Full Text] [Related]
27. Synthetic soluble analogs of galactosylceramide (GalCer) bind to the V3 domain of HIV-1 gp120 and inhibit HIV-1-induced fusion and entry.
Fantini J; Hammache D; Delézay O; Yahi N; André-Barrès C; Rico-Lattes I; Lattes A
J Biol Chem; 1997 Mar; 272(11):7245-52. PubMed ID: 9054420
[TBL] [Abstract][Full Text] [Related]
28. Exploring Viral Interference Using Peptides: Molecular Determinants of HIV-1 Inhibition by a Peptide Derived from Human Pegivirus-1 Envelope Protein E2.
Hoffmann R; Ruegamer T; Schaubächer J; Rohrhofer A; Kirmeß P; Fiebig KM; Schmidt B; Eichler J
ChemMedChem; 2021 Apr; 16(8):1290-1296. PubMed ID: 33378104
[TBL] [Abstract][Full Text] [Related]
29. Recurring conformation of the human immunodeficiency virus type 1 gp120 V3 loop.
Stanfield RL; Ghiara JB; Ollmann Saphire E; Profy AT; Wilson IA
Virology; 2003 Oct; 315(1):159-73. PubMed ID: 14592768
[TBL] [Abstract][Full Text] [Related]
30. Deleted in malignant brain tumors-1 protein (DMBT1): a pattern recognition receptor with multiple binding sites.
Ligtenberg AJ; Karlsson NG; Veerman EC
Int J Mol Sci; 2010; 11(12):5212-33. PubMed ID: 21614203
[TBL] [Abstract][Full Text] [Related]
31. T-cell membrane-associated serine protease, tryptase TL2, binds human immunodeficiency virus type 1 gp120 and cleaves the third-variable-domain loop of gp120. Neutralizing antibodies of human immunodeficiency virus type 1 inhibit cleavage of gp120.
Niwa Y; Yano M; Futaki S; Okumura Y; Kido H
Eur J Biochem; 1996 Apr; 237(1):64-70. PubMed ID: 8620895
[TBL] [Abstract][Full Text] [Related]
32. SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids.
Delézay O; Hammache D; Fantini J; Yahi N
Biochemistry; 1996 Dec; 35(49):15663-71. PubMed ID: 8961929
[TBL] [Abstract][Full Text] [Related]
33. Structural analysis of a highly glycosylated and unliganded gp120-based antigen using mass spectrometry.
Wang L; Qin Y; Ilchenko S; Bohon J; Shi W; Cho MW; Takamoto K; Chance MR
Biochemistry; 2010 Oct; 49(42):9032-45. PubMed ID: 20825246
[TBL] [Abstract][Full Text] [Related]
34. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120.
McKeating JA; Shotton C; Cordell J; Graham S; Balfe P; Sullivan N; Charles M; Page M; Bolmstedt A; Olofsson S
J Virol; 1993 Aug; 67(8):4932-44. PubMed ID: 7687306
[TBL] [Abstract][Full Text] [Related]
35. Tyrosine-sulfated V2 peptides inhibit HIV-1 infection via coreceptor mimicry.
Cimbro R; Peterson FC; Liu Q; Guzzo C; Zhang P; Miao H; Van Ryk D; Ambroggio X; Hurt DE; De Gioia L; Volkman BF; Dolan MA; Lusso P
EBioMedicine; 2016 Aug; 10():45-54. PubMed ID: 27389109
[TBL] [Abstract][Full Text] [Related]
36. NMR studies on the conformation of the CD4 36-59 peptide bound to HIV-1 gp120.
Gizachew D; Moffett DB; Busse SC; Westler WM; Dratz EA; Teintze M
Biochemistry; 1998 Jul; 37(30):10616-25. PubMed ID: 9692951
[TBL] [Abstract][Full Text] [Related]
37. Bacteria binding by DMBT1/SAG/gp-340 is confined to the VEVLXXXXW motif in its scavenger receptor cysteine-rich domains.
Bikker FJ; Ligtenberg AJ; End C; Renner M; Blaich S; Lyer S; Wittig R; van't Hof W; Veerman EC; Nazmi K; de Blieck-Hogervorst JM; Kioschis P; Nieuw Amerongen AV; Poustka A; Mollenhauer J
J Biol Chem; 2004 Nov; 279(46):47699-703. PubMed ID: 15355985
[TBL] [Abstract][Full Text] [Related]
38. The molecular mechanism of two coreceptor binding site antibodies X5 and 17b neutralizing HIV-1: Insights from molecular dynamics simulation.
Zhang Y; Guo J; Huang L; Tian J; Yao X; Liu H
Chem Biol Drug Des; 2018 Jul; 92(1):1357-1365. PubMed ID: 29624884
[TBL] [Abstract][Full Text] [Related]
39. Interaction of the HIV-1 gp120 viral protein V3 loop with bacterial lipopolysaccharide: a pattern recognition inhibition.
Majerle A; Pristovsek P; Mancek-Keber M; Jerala R
J Biol Chem; 2011 Jul; 286(29):26228-37. PubMed ID: 21636577
[TBL] [Abstract][Full Text] [Related]
40. Synthetic multimeric peptides derived from the principal neutralization domain (V3 loop) of human immunodeficiency virus type 1 (HIV-1) gp120 bind to galactosylceramide and block HIV-1 infection in a human CD4-negative mucosal epithelial cell line.
Yahi N; Sabatier JM; Baghdiguian S; Gonzalez-Scarano F; Fantini J
J Virol; 1995 Jan; 69(1):320-5. PubMed ID: 7983725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
